Medical articles today

/* 728x15, */

UPMC Cardiovascular College Recruiting For Severe Coronary Love Disease Study

/* 468x60, */

The UPMC Cardiovascular Institute currently is enrolling participants for a Phase 2 clinical proof to scrutinize if administering a naturally occurring protein improves blood work to the cardiac muscle in patients with severe coronary artery disease.
The study, familiar as Angiogenesis for the Treatment of Coronary Heart Disease (ACORD), is a randomized, double-blind, placebo-controlled trial that compares the employ of a protein at three dose levels with a placebo. The therapy is delivered to the heart muscle by threading a catheter washed-up a meager intersect in the upper leg.
"Other studies hog hinted that this approach can incision the severity of quinsy in patients who have very tired all other treatment options," said Oscar Marroquin, M.D., employer of the UPMC Center for Interventional Cardiology Check and principal investigator of the study. "It appears the protein, called FGF-1, is able to stimulate the growth of fresh blood vessels to get enclosing existing blockages and advance blood flow to the heart."
This test is designed to see whether FGF-1 can assist patients and, whether so, how much should be given. To be eligible for the study, patients must keep a narration of angina or chronic chest anguish that persists in spite of optimal narcotic therapy.
The ACORD analysis is expected to enroll 120 patients, including 10 from the UPMC Cardiovascular Institute, at 30 medical centres throughout the United States.
Source
University of Pittsburgh
/* 468x60, */

Keywords:

upmc, upmc cardiovascular, study upmc, upmc interventional, employer upmc, including upmc
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy